J&J axes eczema drug from $1.25B acquisition

John­son & John­son said an ex­per­i­men­tal eczema med­i­cine didn’t meet its stan­dards for ef­fi­ca­cy, end­ing hopes for a drug that the phar­ma paid $1.25 bil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.